Authors' objectives:

As the second of a 3-part report on this topic, we performed a systematic review of the literature to assess the effect of consumption of omega-3 fatty acids (eicosapentaenoic acid [EPA; 20:5 n-3], docosahexaenoic acid [DHA; 22:6 n-3], and alpha-linolenic acid [ALA, 18:3 n-3])on various cardiovascular disease (CVD) risk factors and intermediate markers of CVD in healthy people, people with dyslipidemia, diabetes, or known CVD.

Authors' results and conclusions: We examined the effect of omega-3 fatty acids on potential CVD risk factors - including lipoproteins, apolipoproteins, blood pressure, hemoglobin (Hgb) A1c, C-reactive protein (CRP), hemostatic factors, platelet aggregation, and markers of diabetes - and intermediate markers of CVD - including coronary artery restenosis, carotid intima-media thickness (IMT), exercise tolerance testing, and heart rate variability. We also assessed correlations between long-chain omega-3 fatty acids intake and tissue phospholipid levels. Among the outcomes we analyzed, omega-3 fatty acids demonstrated a consistently large, significant effect on triglycerides. The trials of triglycerides reported a net decrease in triglycerides of about 10% to 33%. The effect was dose dependent, generally consistent in different populations, and was generally larger in studies with higher mean baseline triglyceride levels. In contrast to studies of fish oils, the single study of a plant oil (ALA) found a net increase in triglycerides. The effect of omega-3 fatty acids on other serum lipids was weaker (up to a 6% increase in HDL). Outcomes for which a small beneficial effect was found with fish oil supplementation include blood pressure (about 2 mm Hg reduction), restenosis rates after coronary angioplasty (14% reduction), exercise tolerance testing, and heart rate variability. For other evaluated outcomes, including measures of glucose tolerance, the effects of omega-3 fatty acids were either small or inconsistent across studies. Across studies, we found a direct relationships between dose of consumed omega-3 fatty acids and changes in measured levels of EPA+DHA, either as plasma or serum phospholipids, platelet phospholipids, or erythrocyte membrane phospholipids. The correlation between dose and change in level appears to be fairly uniform, where 1 g supplementation of EPA and/or DHA corresponds to approximately a 1% increase in EPA+DHA level.

Authors' recommendations: A large, consistent beneficial effect of omega-3 fatty acids was found only for triglyceride levels. Little or no effect of omega-3 fatty acids was found for a variety of other cardiovascular risk factors and markers of cardiovascular disease. The benefits of omega-3 fatty acids on reducing cardiovascular disease are not well explained by the fatty acids' effects on the cardiovascular risk factors we examined. A strong, linear association was found across studies between omega-3 fatty acid intake and tissue levels. Heterogeneity of treatment effect was common among studies across the outcomes evaluated. Given the large amount of heterogeneity across studies, many questions remain about the effect of omega-3 fatty acids in improving potential CVD risk factors and intermediate markers of CVD. Few studies addressed questions related to effect modifiers and only limited conclusions could be made regarding these factors. The optimal quantity and type of omega-3 fatty acid, ratio of dietary omega-6 to omega-3, and duration of treatment remain undefined. Future research is needed to address these issues.

Authors' methods: Systematic review

Project Status: Completed

URL for project: http://www.ahrq.gov/clinic/tp/o3cardrisktp.htm

Year Published: 2004

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: Agency for Healthcare Research and Quality

Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;

Contact Name: martin.erlichman@ahrq.hhs.gov

Contact Email: martin.erlichman@ahrq.hhs.gov

Copyright: Agency for Healthcare Research and Quality (AHRQ)